Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Learn which low fee index funds beat the market in 2024 and how they can fit into a retirement strategy. This guide highlights top performers and practical steps for investors.
28,527 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Chipotle and Microsoft have taken divergent paths in 2026. CMG rides restaurant-demand strength while MSFT grapples w...
Amazon’s stock is sliding this year as cloud rivals tighten the race and the company leans into a big AI investment. ...
UniCredit announces a $40 billion bid for Germany’s second-largest bank with a 4% premium, but early signals point to...
Bitcoin sits at a regulatory crossroads as Consensus 2026 brings renewed debate over the Clarity Act. Hayes argues th...
A Dallas-based brokerage joins Compass, expanding its footprint across Dallas–Fort Worth and Austin with a team of 10...
NVIDIA's Jensen Huang just signaled a major pivot that could reshape the PC landscape. This article breaks down the i...
As crypto and precious metals slide, investors eye Robert Kiyosaki’s stance. He emphasizes context over price, signal...
Brokers are turning to AI-enabled property management as market forces slow home sales, embracing recurring revenue t...
Palantir sits around $130 as Michael Burry’s $46 valuation challenge re-emerges, forcing a sharper look at growth, ma...
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Los Angeles-based luxury real estate brokerage Resident is expanding into Napa Valley, signaling a broader push into ...